A drug used to treat advanced ovarian cancer caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is used in patients who have already received other anticancer drugs. It is also being studied in the treatment of other types of cancer. PARP inhibitor AZD2281 blocks an enzyme involved in many cell functions, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. PARP inhibitor AZD2281 may cause cancer cells to die. It is a type of targeted therapy agent and a type of poly (ADP-ribose) polymerase inhibitor. Also called AZD2281, Lynparza, and olaparib.